StemCell Therapy

Advised nutrition tips to improve better health and longevity!

Good nutrition is a critical part of health and development. According to the World Health Organization (WHO), better nutrition is related to improved health at all ages, a lower risk of diseases, and longevity.

People can find it difficult or confusing to navigate the amount of nutrition information now available, and many sources have differing views.

This article offers science-based nutrition tips to help someone lead a healthier lifestyle.

Following these nutrition tips will help a person make healthy food choices.

Including some protein with every meal can help balance blood sugar.

Somestudiessuggest higher protein diets can be beneficial for type 2 diabetes.

Otherresearchindicates balancing blood sugar can support weight management and cardiovascular health.

According toresearch, omega-3 fatty acids in oily fish are essential for cell signaling, gene expression, and brain and eye development.

Somestudiesindicate that omega-3 fatty acids can reduce the risk of cardiovascular disease.

Otherresearchsuggests the anti-inflammatory properties of omega-3 may effectively manage the early stages of degenerative diseases such asAlzheimers diseaseandParkinsons disease.

TheAmerican Heart Association (AHA)recommend people eat whole grains rather than refined grains.

Whole grains contain nutrients such as B vitamins, iron, and fiber. These nutrients are essential for body functions that include carrying oxygen in the blood, regulating the immune system, and balancing blood sugar.

The saying eat a rainbow helps remind people to eat different colored fruits and vegetables.

Varying the color of plant foods means that someone gets a wide variety of antioxidantsbeneficialto health, for example, carotenoids and anthocyanins.

Dark green leafy vegetables are a great source of nutrition, according to theDepartment of Agriculture (USDA).

Leafy greens are rich in vitamins, minerals, and antioxidants.

The USDA suggest that folate in leafy greens may help protect against cancer, while vitamin K helps prevent osteoporosis.

People should limit their intake of saturated fats while avoiding trans fats, according to theUSDA.

A person can replace these fats with unsaturated fats, which they can find in foods such as avocado, oily fish, and vegetable oils.

As part of the Mediterranean diet, extra virgin olive oil has benefits to the heart, blood pressure, and weight, according to a2018 health report.

A person can include extra virgin olive oil in their diet by adding it to salads or vegetables or cooking food at low temperatures.

According to theAHA, eating one serving of nuts daily in place of red or processed meat, french fries, or dessert may benefit health and prevent long-term weight gain.

The AHA suggest that Brazil nuts, in particular, may help someone feel fuller and stabilize their blood sugar.

According to theAHA, fiber can help improve blood cholesterol levels and lower the risk of heart disease, obesity, and type 2 diabetes.

People can get enough fiber in their diet by eating whole grains, vegetables, beans, and pulses.

Researchsuggests that plant-based diets may help prevent overweight and obesity. Doctors associate obesity with many diseases.

According to some studies, including more plant foods in the diet couldreducethe risk of developing diseases such as diabetes and cardiovascular disease.

Beans and pulses are a good source of protein for people on a plant-based diet. However, those who eat meat can eat them on a few meat-free days a week.

Beans and pulses also contain beneficial fiber, vitamins, and minerals.

Someresearcheven says pulses may help people feel fuller and lose weight.

Drinking plenty of healthy fluids has numerous health benefits. Health experts recommend these tips:

Drinking enough water every day is good for overall health and can help manage body weight, according to theCenters for Disease Control and Prevention (CDC).

Drinking water can prevent dehydration, which can be a particular risk forolder adults.

If someone does not like plain water, they can add some citrus slices and mint leaves to increase the appeal, or drink herbal teas.

A2017 studysuggests that moderate coffee consumption of 35 cups a day can reduce the risk of:

According to the same review, the recommended amount reduces to 2 cups per day for pregnant and lactating people.

According toresearch, catechins in green, black, and other herbal teas may have antimicrobial properties.

Herbal teas, such as mint, chamomile, and rooibos, are caffeine-free and help keep someone hydrated throughout the day.

It is important to cut back on food and drink that may have harmful health consequences. For example, a person may want to:

According toresearch, dietary sugar, dextrose, and high fructose corn syrup may increase the risk of cardiovascular disease and metabolic syndrome.

People should look out for hidden sugars in foods that manufacturers label as names ending in -ose, for example, fructose, sucrose, and glucose.

Natural sugars, such as honey and maple syrup, could also contribute to weight gain if someone eats them too often.

Dietary Guidelines For Americansrecommend that if someone consumes alcohol, it should be in moderation.

They advise up to one drink per day for females and up to two drinks per day for males.

Excessive drinking increases the risk of chronic diseases and violence, and over time, can impair short and long-term cognitive function.

TheCDCassociate frequently drinking sugary drinks with:

People should limit their consumption of sugary drinks and preferably drink water instead.

A large prospective study in theBritish Medical Journalindicates that U.S. adults eating more red and processed meat had higher mortality rates.

Participants who swapped meat for other protein sources, such as fish, nuts, and eggs, had a lower risk of death in the eight-year study period.

According to a review inNutrients, eating ultra-processed foods can increase the risk of many diseases, including cancer, irritable bowel syndrome, and depression.

People should instead consume whole foods and avoid foods with long lists of processed ingredients.MEDICAL NEWS TODAY NEWSLETTERStay in the know. Get our free daily newsletter

Expect in-depth, science-backed toplines of our best stories every day. Tap in and keep your curiosity satisfied.Enter your emailSIGN UP NOW

Yourprivacyis important to us

There are several steps a person can take to improve their health in addition to consuming healthful foods and drinks.

A 2019 review inNutrientssuggests that a high quality, balanced diet supports microbial diversity and can influence the risk of chronic diseases.

The authors indicate that including vegetables and fiber are beneficial to the microbiome. Conversely, eating too many refined carbohydrates and sugars is detrimental.

The recommended dietary allowance for vitamin D is15 micrograms or 600 international unitsper day for adults.

Many people get some of their vitamin D from sunlight, while it is also in some foods.

People with darker skin, older adults, and those who get less exposure to sunlight such as during winter or in less sunny climates may need to take a vitamin D supplement.

Being aware of portion sizes can help people manage their weight and diet.

TheUSDAhave helpful information about portion sizes for different food patterns.

People can adapt the guidelines to suit their cultural or personal preferences.

Using herbs and spices in cooking can liven up a meal and have additional health benefits.

A2019 reviewsuggests that the active compounds in ginger may help prevent oxidative stress and inflammation that occurs as part of aging.

Curcumin in turmeric is anti-inflammatory and may have protective effects on health, according toresearch.

Garlic has manybenefits, including anti-inflammatory, antimicrobial, and antioxidant properties.

Intermittent fasting involves not eating either overnight or some days of the week. This may reduce energy intake and can have health benefits.

According to a2020 review, intermittent fasting may improve blood pressure, cholesterol levels, and heart health.

TheAmerican Society for Nutritionsay that keeping a food journal can help people track calories, see how much they are eating, and recognize food habits.

Keeping a food journal could help someone who wants to maintain a moderate weight or eat a more healthful diet.

Apps, such asMyFitnessPal, can also help someone achieve their goals.

Raw fruits and vegetables can contain harmful germs that could make someone sick, according to theCDC. They advise thatSalmonella, E.coli,andlisteriacause a large percentage of U.S. foodborne illness.

Always wash fresh produce when eating them raw.

Researchsuggests that microwaving food in plastic containers can release phthalates, which can disrupt hormones.

Experts recommend heating food in glass or ceramic containers that are microwave-safe.

Many people eat the same meals regularly. Varying foods and trying different cuisines can help someone achieve their requirednutrient intake.

This can be particularly helpful when trying to eat a broader range of vegetables or protein.

In a2017 study, mindful eating helped adults with obesity eat fewer sweets and manage their blood glucose.

Anotherstudysuggests mindfulness can bring greater awareness to food triggers and habits in people with diabetes.

Nutrition is an essential part of health, and people can start leading a healthful lifestyle by making small changes to their diet.

It is also important to remember other key aspects of health, such as exercise and activity, stress strategies, and adequate sleep.

Source: Advised nutrition tips to improve better health and longevity! THE HOLLYWOOD MIRROR

Go here to see the original:
Advised nutrition tips to improve better health and longevity! - Vancouver Health Coach

How we grow our food has a really big impact on the quality of that food and that means that when the quality of the food is better, the quality of your health and the quality of our planet is better explains Mary Purdy, Rd, Integrative & Eco-Conscious Registered Dietitian, on her podcast.

No matter how many times you enjoy a salad for lunch, the nutritional value thats on your plate has already been determined long before you placed your order.

Agricultural techniques that are more eco-friendly tend to make produce and foods that are healthier for you explains Mary.

We all want to consume food rich in nutritional value. However, in order to do this, we need to be conscious of how our food is produced and presented. Not many people think that food production can have a great impact on the nutritional quality of food, especially when you realize that the nutritional value of food has faced a steady decline.

Dont believe us? Well, one study found that, between 1975 and 1997, average calcium levels in 12 vegetables dropped by 27%, vitamin A levels by 21%, and vitamin C levels by 30%. A separate British study found that between 1930 and 1980, the average calcium content had depleted 19%, iron 22%, and potassium 14%.

So whats the reason for the decline in the nutritional value of our food? The answer is a simple one: soil depletion. The fact of the matter is that if we really want total control of our health, of the quality of our food, and frankly the longevity of our planet, then we need to learn to take better care of our soil microbiome.

The soil microbiome is this neuro-network in the plant that can affect the plant at a genetic level. If we can create healthy soil, not only will it help sequestrate carbon (reduce the amount ofcarbondioxide in the atmosphere with the goal of reducing global climate change) but it will also help to retain water. For every 1% soil organic matter that we build on our farm, we can retain 170 000 gallons of water per acre explains CEO and co-founder of Nutrition for Longevity Jennifer Maynard, who also has a twenty-plus year career in biotech and pharmaceutical medicine area, When you are building up that soil organic matter, youre creating an environment for the soil microbiome to thrive and this builds up phytonutrients which are essentially superfoods rich in color and nutrients.

A United Nations report revealed that a third of the planets land was severely degraded through erosion, salinization, compaction, acidification, and chemical pollution, and fertile soil was being lost at a rate of 24bn tonnes a year. Its easy to see why so much focus has been placed on the health and quality of the soil.

If we really want to protect the health of our soil, then its best to re-evaluate our farming practices. We may need to turn away from commercial farming practices to something more sustainable like regenerative farming.

Regenerative farming is all about reconstructing the soil. A lot of current agricultural practices are all about constructing the soil. Its all about pillage and getting rid of as many weeds as possible. This is done in a very mechanized way that is low on labor costs and often using a lot of chemicals explains Maynard, who goes on to mention that the US used to have, on average 11% soil organic which is an indicator of soil structure and now they have an average 1% and this is why regenerative farming is becoming a hot topic.

In 2015, the then UN Director-General Jos Graziano da Silva warned at the time that Further loss of productive soils would severely damage food production and food security, amplify food-price volatility, and potentially plunge millions of people into hunger and poverty.

As mentioned, the purpose of regenerative farming is to improve the health and quality of the soil. According to Maynard, theyve noticed 700 times less soil erosion by using regenerative farming. Furthermore, healthy soil means a healthy soil microbiome and this means a healthier you.

In fact, a study published in PLoS One found that a healthy soil microbiome full of necessary bacteria is more likely to produce nutrient-dense food, which can then promote better health.

The Intergovernmental Panel on Climate Change (IPCC), which is the United Nations body for assessing the science related to climate change, found that 23% of the total global greenhouse gas GHG emissions are directly related to agriculture, forestry, and other types of land use. That said, a report from the Rodale Institute, a nonprofit organization that supports research into organic farming, regenerative farming has the potential to reduce climate change instead of contributing to it.

How so?

By helping to maximize the carbon dioxide pulled from the atmosphere by plant growth and minimize the loss of that carbon once it is stored in the soil.

Infiltration refers to the soils ability to absorb and hold water, which means less runoff. This then translates to less erosion and pollution as a result of the reduction in runoff water.

According to the Food and Agriculture Organization of the United Nations, natural springs that had dried up many years ago, have begun to flow again due to new regenerative farming practices.

Regeneratively grown plants are put under more stress because we dont use chemicals to defend them. So, they have to draw on their microorganisms to cope with stress. One of the main mechanisms that they do is communicate with the plant to create more phytonutrients, explains Maynard.

Phytonutrients are chemicals found in plant products that help to provide antioxidant and anti-inflammatory benefits. Studies have found that they exist in abundance when it comes to non-commercially farmed produce.

A study from Newcastle University found that organic fruits and vegetables deliver between 20 and 40 percent more antioxidants than conventional fruits and vegetables. Additionally, a separate study published in theBritish Journal of Nutrition found that organic dairy and meat contain about 50% more omega-3 fatty acids.

Theres still a long way to go before we can adopt regenerative farming as the new method of farming. In the meantime, we can look at other innovative ways of producing food.

One such technique could be aquaponics. Maynard describes it as an ancient farming technique that can be traced back to the Aztecs, and which uses about 1% of the water of conventional farming.

With aquaponics, you grow fish and other aquatic animals in an effort to grow plants without soil. The plants are fed the aquatic animals waste and, in return, the vegetables clean the water that goes back to the fish. While this happens, microbes gather in the spaces between the roots of the plant and convert the fish waste and the solids into substances the plants can use to grow.

Maynard sees it as a farming technique that is still environmentally friendly and which allows us to grow food worldwide, especially with the rise in natural disasters.

If you want to start making little changes, start asking where your food comes from. In addition, to shopping organic, you can also start to grow a little of your own food. According to Maynard, once people understand how challenging it is to grow food, theyll likely become more conscious about their food waste.

Davis, D. R., Epp, M. D., & Riordan, H. D. (2004). Changes in USDA food composition data for 43 garden crops, 1950 to 1999.Journal of the American College of Nutrition,23(6), 669682. https://doi.org/10.1080/07315724.2004.10719409

Mayer, Anne-Marie. (1997). Historical changes in the mineral content of fruits and vegetables. British Food Journal. 99. 207-211. 10.1108/00070709710181540.

Reganold, J. P., Andrews, P. K., Reeve, J. R., Carpenter-Boggs, L., et al. (2010). Fruit and soil quality of organic and conventional strawberry agroecosystems.PloS one,5(9), e12346. https://doi.org/10.1371/journal.pone.0012346

rednicka-Tober, D., Baraski, M., Seal, C. J., Sanderson, R., et al. (2016). Higher PUFA and n-3 PUFA, conjugated linoleic acid, -tocopherol and iron, but lower iodine and selenium concentrations in organic milk: a systematic literature review and meta- and redundancy analyses.The British journal of nutrition,115(6), 10431060. https://doi.org/10.1017/S000711451600034

Read the original:
You Really Need To Care About How Your Food Is Grown - Longevity LIVE

Abstract

Neutralizing antibody responses to SARS-CoV-2, though often of limited longevity, have generally been assumed to be protective against COVID-19 disease.

Prior analyses on thoracic lymph nodes and peripheral blood suggested a dysregulated humoral immune response early in COVID-19, including defective bcl-6+ follicular helper T cell TNF- production and loss of transitional and follicular B cells in severe disease. The cumulative data from recent publications suggested association of an aberrant extrafollicular (EF) B cell response with COVID-19 disease course. Prior work by Woodruff et al. characterized a unique group of IgD and CD27 double-negative (DN) EF B cells in systemic lupus erythematosus, associating the CXCR5negCD21negCD11c+ (DN2) subset with increased disease activity and poor clinical outcomes.

By applying this knowledge to high-dimensional B cell phenotyping stratified according to clinical COVID-19 disease severity, the authors not only validate previously known immune associations including elevated plasma IL-6 concentration, but also reveal that patients with life-threatening COVID-19 demonstrate significant expansion of peripheral blood DN2 cells, activated nave B cells, and antibody secreting cells (ASCs). They delineate a CD21negCD11cneg (DN3) B cell population that, when elevated in blood with two other EF populations including DN2 cells, associates with critical illness and high mortality in COVID-19 patients despite early neutralizing antibody responses. Elevated plasma C-reactive protein (CRP) also correlated with COVID-19 disease severity. The cumulative data offer a new perspective on pathogenic B cell responses in COVID-19 and support hypothesis-driven testing of the combined serum and B-lineage immune signature as a biomarker panel to screen for high-risk COVID-19 disease during infection and therapeutic interventions. These studies also provide insights into B cell effector pathways to consider in targeted immune therapies and COVID vaccine development.

Read the original post:
B careful: Humoral responses and COVID-19 severity - Science

The Premier Leagues longest-serving manager is discussing the concept of dynasty in football when, somewhere along the way, he ends up at birthday meals.

When I was growing up you went out for dinner for special birthdays, Sean Dyche recalls.

Now, families go out once, twice a week. Its part of the culture of life. This is life developing.

Dyches point is that the shift in modern culture has some good sides as well as the bad that, he believes, modern football reflects, causing the ferocious turnover of managers.

The average life expectancy of a manager now is around 14 months, Dyche says, compared to three years in the 1990s. The trouble now is the demand for change is almost instant, he tells i. Everyone wants the fridge delivered a day earlier, and they want a longer warranty. And why isnt it cheaper? And we all get on the internet and search around.

We use it for two years and decide even though theres nothing wrong with it we want something else, so we get rid of that. We get a new one in. That kind of mentality is in life, therefore the chances are its going to go into your thinking in sport. Thats why the culture is changing.

Dyche has agreed to this interview after launching the Sean Dyche Family Scholarship, a 15,000 sponsorship spread over three years for a prospective student at the University Campus of Football Business. But as we twist and turn through topics, it transcends into The World According to Sean Dyche: probabilities, possibilities, modern culture, longevity, his football philosophy.

Towards the end he will describe it as the longest interview ever. Are we doing a book? he asks. Though it would take more than one or possibly a Lord of the Rings-esque tome to fit in everything Dyche knows and thinks about life and football.

When Dyche gets going he sounds more like a young tech entrepreneur pitching their latest mobile app to venture capitalists, on the verge of sealing an investment worth hundreds of millions. Fast-talking, passionate, brimming with ideas. Not a man nearing his half century who has become a stalwart of English football and a household name after eight years spent at Burnley.

There are few managers who can discuss with such authority the ingredients for longevity at a football club. Perhaps Sir Alex Ferguson with his 26 years at Manchester United, Arsene Wenger with 21 at Arsenal, David Moyes with 11 at Everton.

So how has Dyche done it in the modern era when managerial lifespans have shrunk?

Having good staff who are different people to you, so you get real opinions rather than everyone joining in with my opinion thinking Im right, because Im not always right, he explains. Only 99.9999 per cent of the time.

The players are vital, recruitment is vital. Weve got a good alignment at Burnley. When I first joined the one thing I mentioned was a one-club mentality. I really believe in it. Most successful football clubs have a unity running through them. It sounds easy, but its not easy to build that mentality and get all noses pointed in the right direction.

Ive a good feeling about the way we work: the respect, the authenticity, the honesty of the way people are here, the way they treat people.

Dyches view of football management is shaped not by those longstanding managers who came before, but by his 20-year playing career. I was a bit of a journeyman, he says.

He didnt play regularly in the Premier League, but he played everywhere else, and won four promotions. Only during one of them did he realise the signs of longevity were missing, at Bristol City. True to that hunch, they were relegated the following season.

I remember even as a player thinking theres an alignment through the club, the manager, the coaches, the staff, the players, the delivery of the performance, the fans gluing into what the team stands for.

He learnt about alignment and how business worked from his dad, Alan, who was a management consultant for British Steel. And, he adds, I had an instinct for it.

And off we go: A lot of it involves simple things. Honesty is essential. Truthfulness with players. The pride, the passion, the individual responsibility, the will, the desire to work.

Eventually you build a culture. Once you get that right, as long as youve got some quality in your building, the culture is the glue that holds it all together. The way you work, the environment, then that allows the talent of the individual to flourish.

You need a lot of people with you, carrying that same message. Its very difficult to do it on your own. Theres a lot of convincing, a lot of cajoling. Then you get this flow and it starts spreading, and it spreads through your staff into the players, and into the feel of a club. But it takes time.

Time, though, is footballs most precious commodity. Blink and you miss the tweak to that rule, the latest signing at one club, the firing and hiring at another.

Yet football, Dyche says, is changing in other ways, too. A life in football is no longer shut off from those kids who love the game but are not great at playing it. It used to be that those who tried to work in football and had not played were sneered at or ignored. That has slowly changed.

Jose Mourinho is the most successful example: Sir Bobby Robsons interpreter to assistant at Barcelona, to one of the games leading managers. Dyche cites others.

Brendan Rodgers had been in the system at Reading, he got injured, was out of the game at 19, but he had a feel of it. Mark Warburton was an apprentice footballer, didnt make it as a pro, played a bit of non-league.

The open mindedness of the way coaching works now is that you can learn skillsets and still be very successful. Jose is definitely an example of that, as is Gerard Houllier, Arsene Wenger. There are many more who have come through different pathways. Its forever opening. They were some who have opened the minds of many and that continues. The world is changing in professional sport.

Dyche could end up supporting that next coach, sporting director or football leader who never played the game. He launched his familys scholarship after consulting with his son and daughter Max, 17, and Alicia, 15 and his wife Jane. They were all behind it. Jane completed a degree in business and Alicia looks to be heading down an educational path. Max is a promising footballer.

I did a bit of thinking as a dad and wanted to support someone on their journey to doing well in life, possibly someone not finding it easy to get that support, he says.

His own journey is far from over and exciting adventures lie ahead. Burnley are set for a change of ownership, with multiple parties tabling offers, meaning funds will be available for Dyche to push on. But is it even possible to take Burnley to the next level, in this world of footballs global behemoths?

There are possibilities and probabilities, Dyche begins.

Deep breath, as we plunge down another Dyche waterfall: Probably, without a financial shift, then its very difficult to compete beyond the reality of competing to be in the Premier League. Thats a probability.

Possibilities, thats a different ball game. We finished seventh. Then we finished 10th. Two out of the last three seasons. Nobody wouldve given us a chance of that. Things are achievable in a possible mindset for different things, but you have to sometimes register the probabilities. Probably life at Burnley is going to be working hard to be in the Premier League and trying to inch away at things, rather than make big strides forward at any given time. Because when you get to a certain level, finance becomes really important.

Thats something Burnley has lagged behind the truth of the market in, weve got to stretch that going forward, stretch the mentality of investment to allow Burnley to continue growing on the pitch. There are a lot of good things going on off the pitch, but they will only work if the team is working and the team will need an ongoing investment platform to take it further.

We resurface for air. Dyche looks and sounds as though he could carry on forever.

View post:
The world according to Sean Dyche: Im not always right only 99.9999 per cent of the time - iNews

Deta Hedman will make her PDC World Championship debut at the age of 61 after a superb display at the PDC Women's Series.

Hedman is seen as one of the leading pioneers in Women's Darts with 'The Heart of Darts' despite never winning the BDO World Championship, one of the most successful of all time.

She will now take on Andy Boulton at the Alexandra Palace with a rapturous reception likely for the former two time World Master.

So what is the secret to the longevity of Hedman? She believes that it is still having the enjoyment for the game and believes she will be involved as long as is possible.

"I think it's having the love and enjoyment that I still do when I play and meeting up with some great friends," she said to Sky Sports.

"I'll just see where it takes me. I will probably always be involved in the game until I drop or when my memory fails me but I'm still loving it. I have my moments!"

In terms of the future of the ladies game, Hedman believes that if given the opportunity, the glass ceiling can firmly be smashed.

"You have Mikuru [Suzuki], Lisa and Fallon who have taken the game to another level. You have another young lady called Beau Greaves who I think is going to be phenomenal.

"If the opportunity is there like the men's in the PDC then I think you will see the ladies game change again. The standard will be so high it's unbelievable. It is there. Some of the ladies do have the game and it's like any sport. It's whether you really want it."

Read the original:
Hedman on longevity ahead of World Championship debut: "I will probably always be involved in the game until I drop" - Dartsnews.com

The Navajo Nation is rolling out new coronavirus restrictions as COVID-19 cases surge and hospitals are becoming overwhelmed by an influx of patients.

Navajo Nation President Jonathan Nez on Thursday announced an extension of a lockdown order that requires all residents to stay at home and on the reservation unless obtaining essential food, medication and other supplies, as well as exemptions for essential workers.

Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.

Residents have been advised against gathering with people from outside their immediate household and to wear a mask in public.

The lockdown was initially expected to expire on Sunday but has been extended until Dec. 27 following an alarming surge of infections. As of Friday, 17,310 cases have been reported with 663 deaths.

A 57-hour weekend curfew will also kick off at 9 p.m. on Dec. 11 and last for three weeks.

The move comes as several medical and health care workers said the Navajo Nation is in a major health care crisis and pleaded with the public to stay home and adhere to public health guidelines to slow the spread of the virus during a virtual forum hosted by Nez and Vice President Myron Lizer.

Loretta Christensen, chief medical officer for Navajo Area Indian Health Service, told officials the coronavirus situation is leading to a shortage of hospital beds, oxygen supplies and medical personnel.

We have been in a state of emergency since the pandemic began here on the Navajo Nation, but that has now elevated to a major health care crisis, Nez said.

Our health experts are now saying that the current wave or surge is far more severe and troublesome than the wave that we saw in April and May, perhaps four or five times large according to projections, he said.

Nez on Thursday requested the Trump administration issue a Major Disaster Declaration to free up additional infrastructural and financial resources to better equip the nation to tackle the outbreak.

The Navajo Nation and other Native American communities have been disproportionately affected by the coronavirus pandemic.

According to the Centers for Disease Control and Prevention, American Indian or Alaska Native individuals are1.8 times more likely than their white counterparts to contract the virus, four times more likely to be hospitalized and2.6 times more likely to die from the infection.

The situation in the Navajo Nation comes as the U.S. reportedmore than 210,000 cases in a single day on Thursday, the highest figure yet, and more than 2,700 COVID-19 deaths.

WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW

CDC CUTS LENGTH OF COVID-19 QUARANTINE TIME AFTER EXPOSURE

UK BECOMES FIRST WESTERN NATION TO AUTHORIZE COVID-19 VACCINE

CDC DECIDES WHO WILL RECEIVE FIRST DOSES OF COVID-19 VACCINES

CORONAVIRUS EPIDEMIC WAS SPREADING IN US LAST CHRISTMAS, LONG BEFORE IT WAS IDENTIFIED IN CHINA, NEW STUDY FINDS

FAUCI CONFIRMS COVID-19 VACCINE COULD BE READY BY LATE DECEMBER, EARLY 2021

Original post:
Navajo Nation facing 'major health care crisis' as outbreak worsens | TheHill - The Hill

Medicine has always been personalized what has changed are the tools available that allow us to provide better care for you. The Institute for Personalized Medicine is Penn State Health's commitment to advancing health care for our community through the use of modern technology and more effective tools.

In the past, doctors based treatments on research that studied broad groups of people, finding what is most likely to help a majority of patients. While this approach has been successful, its not always efficient since each of us is different. Our genetics and our biology are unique to us, so treatments that work best for one person may not work best for another.

Personalized medicine is the use of individual characteristics to tailor treatments to the person. For example, one person may respond to a medicine differently than another because of their genetics. By knowing what that genetic difference is, doctors can look for the same in future patients and prescribe medication accordingly helping to recover faster.

Penn State Institute for Personalized Medicine gives scientists the tools to develop research studies seeking this information, and future therapies for patients.

Continue reading here:
Personalized Medicine | Penn State Health

DUBLIN, Nov. 11, 2020 /PRNewswire/ -- The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Story continues

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2023.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Finally the bibliography contains over 750 selected publications cited in the report. The report is supplemented by 88 tables and 50 figures.

Key Topics Covered:

Part I: Scientific Basis & Technologies

Executive Summary

1. Basic Aspects

2. Molecular Diagnostics in Personalized Medicine

3. Pharmacogenetics

4. Pharmacogenomics

5. Role of Pharmacoproteomics

6. Role of Metabolomics in Personalized Medicine

7. Personalized Biological Therapies

8. Personalized complementary & Alternative Therapies

9. Personalized Medicine in Major Therapeutic Areas

10. Personalized Therapy of Cancer

11. Development of Personalized Medicine

12. Ethical, Legal and Regulatory Aspects of Personalized Medicine

Part II: Markets & Companies

13. Markets for Personalized Medicine

14. Companies Involved in Developing Personalized Medicine

15. References

For more information about this report visit https://www.researchandmarkets.com/r/ty8o34

Source: Jain PharmaBiotech

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-2029-301170831.html

SOURCE Research and Markets

Read more here:
Personalized Medicine Market, 2029

LONDON--(BUSINESS WIRE)--The global biochip market size is poised to grow by USD 19.71 billion during 2020-2024, progressing at a CAGR of 22% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

Personalized medicines growing popularity and demand is expected to drive the growth of the Biochip market. The medicines are personalized as per the patients needs which suits the individual characteristics of the person is a multi-faceted approach. This improves the ability to diagnose and effectively treat the disease as this technique facilitates early diagnosis. These biochips play an important part in the development of these medicines, as it improves the ability to diagnose and effectively treat the disease. It is also expected that during the forecast period the growing incidences of genetic and terminal diseases will influence the demand for personalized medicine for targeted drug development. This will increase the demand for biochips which will result in the growth of this industry.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Report Highlights:

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Rising Use of Biochips in Safety Detection of Agriculture Products will be a Key Market Trend

The rising use of biochip technology in the agriculture industry is turning out to be one of the major trends in the biochip industry. Biochip helps in the detection of pathogenic microorganisms, biological toxins, pesticide residues, and antibiotics. Microchips help in providing early warning to agricultural products' monitoring with a rapid response system and, thus, enhance the agricultural products' safety detection system. Therefore, significantly helping the agriculture industry from the loss it faces every year.

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Biochip Market 2020-2024: Key Highlights

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original post:
Biochip Market | Increased Popularity of Personalized Medicine to Boost the Market Growth | Technavio - Business Wire

THE HAGUE, Netherlands, Dec. 5, 2020 /PRNewswire/ --The HARMONY Alliance announces new analyses demonstrating how Big Data can facilitate personalized medicine in patients with blood cancers, also known as Hematologic Malignancies. Using data from around 12,000 AML and MM patients comprised in the HARMONY Big Data Platform, the researchersobtained fascinating insights into the molecular basis of Acute Myeloid Leukemia (AML) and developed an improved risk stratification model for Multiple Myeloma (MM). These results are presented during the 62nd American Society of Hematology Annual Meeting.

Harmony Alliance Provides Novel Insights into Acute Myeloid Leukemia Based on a Pan-European NGS Data Collection (abstract 1077- Bullinger et al)

Lars Bullinger, HARMONY Partner Charit Berlin, Germany:

"We have analyzed genomic data of 4,986 patients with AML. We could confirm the co-occurrence of certain mutations. In addition, we obtained insight into which mutations occur first and which later in the disease process. We have also investigated the association of mutation patterns with clinical outcomes such as remission, relapse, and survival. For instance, many patients with high-risk mutation patterns benefit only little from an allogeneic stem cell transplantation (alloSCT), but we found specific high-risk genotype combinations that predict a much larger survival benefit."

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7,077 Patients Collected By European Myeloma Network within Harmony Big Data Platform (abstract 1329- D'Agostino et al)

Mattia D'Agostino, HARMONY Partner University of Turin, Italy:

"Clinical outcomes for patients with MM vary greatly, with survival ranging from a few months to more than ten years. Investigating data from 7,077 patients with newly diagnosed MM, we discovered that patients who are currently considered as 'intermediate-risk patients' constitute a quite diverse group with varying risk of progression or death. We identified a new prognostic system identifying 4 risk classes. With this model, about half of the patients can be classified as low or low-intermediate risk, and about half of them can be classified as intermediate-high or high risk. Oncologists can use our improved risk stratification model to better estimate patients' prognosis at the time of MM diagnosis. Moreover, this model favors the design of MM treatments tailored according to the individual risk of each patient."

Comprising data from 45,000 patients with blood cancers, makes the HARMONY Big Data Platform one of the largest of its kind in the world. HARMONY scientists use the Platform to characterize the molecular landscape of Hematologic Malignancies, understand their pathophysiology, and identify novel drug targets. Big data analytics has the potential to transform the treatment of patients with blood cancers. The ability to personalize the treatment of a patient based on molecular understanding of a disease or risk stratification will provide treatment strategies in the future to optimize outcomes for the patients.

More information

SOURCE HARMONY Alliance

https://www.harmony-alliance.eu

Original post:
New data from HARMONY demonstrate the power of Big Data analytics to inform personalized medicine in blood cancer - PRNewswire

News Release

Friday, December 4, 2020

Previously unknown genetic connection could be a target for gene therapy.

A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntingtons disease.

This large, international project, which included a collaboration between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), opens a potentially new avenue for diagnosing and treating some individuals with FTD or ALS.

Several neurological disorders have been linked to repeat expansions, a type of mutation that results in abnormal repetition of certain DNA building blocks. For example, Huntingtons disease occurs when a sequence of three DNA building blocks that make up the gene for a protein called huntingtin repeats many more times than normal. These repeats can be used to predict whether someone will develop the illness and even when their symptoms are likely to appear, because the more repeats in the gene, the earlier the onset of disease.

It has been recognized for some time that repeat expansion mutations can give rise to neurological disorders, said Sonja Scholz, M.D., Ph.D., investigator, NINDS Intramural Research Program. But screening for these mutations throughout the entire genome has traditionally been cost-prohibitive and technically challenging.

Taking advantage of technology available at NIH, the researchers screened the entire genomes from large cohorts of FTD/ALS patients and compared them to those of age-matched healthy individuals. While several patients had a well-established genetic marker for FTD/ALS, a small subset surprisingly had the same huntingtin mutation normally associated with Huntingtons disease. Remarkably, these individuals did not show the classical symptoms of Huntingtons but rather those of ALS or FTD.

None of these patients symptoms would have clued their physicians into thinking that the underlying genetic cause was related to the repeat expansion we see in Huntingtons disease, said Dr. Scholz.

She continued by explaining that whole genome sequencing is changing how neurological patients can be diagnosed. Traditionally, this has been based on which disease best fit the overall symptoms with treatment aimed at managing those symptoms as best as possible. Now, clinicians can generate genetically defined diagnoses for individual patients, and these do not always align with established symptom-based neurological conditions.

Our patients simply dont match a textbook definition of disease when it comes to which mutation produces which symptoms. Here we have patients carrying a pathogenic huntingtin mutation but who present with FTD or ALS symptoms, said Dr. Scholz.

One implication of these findings is that, if successful, these therapies could be applied to the small subset of FTD and ALS patients with that mutation as well. The researchers note that, while the number of FTD/ALS patients seen with the Huntingtons-linked mutation is small (roughly 0.12-0.14%), adding genetic screening for the mutation to the standard diagnostic procedure for patients showing symptoms of FTD or ALS should be considered.

Because gene therapy targeting this mutation is already in advanced clinical trials, our work offers real hope to the small number of FTD and ALS patients who carry this mutation, said Bryan Traynor, M.D., Ph.D., senior investigator, NIA Intramural Research Program. This type of large-scale international effort showcases the power of genomics in identifying the molecular causes of neurodegenerative diseases and paves the way for personalized medicine.

This research was supported by the Intramural Research Program of the National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke; project numbers 1ZIAAG000935, 1ZIANS003154, 1ZIANS003033, 1ZIANS003034), the Intramural Research Program of the National

NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIAs Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Dewan R. et al. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron. November 25, 2020. DOI:10.1016/j.neuron.2020.11.005

###

View original post here:
NIH researchers link cases of ALS and FTD to a mutation associated with Huntington's disease - National Institutes of Health

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that its virtual Special Meeting of Stockholders, scheduled for December 1, 2020, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Special Meeting will be reconvened December 30, 2020 at 3 p.m. CST and will be conducted via live audio webcast at http://www.virtualshareholdermeeting.com/POAI2020SM, so as to allow more opportunity for stockholders to vote on all proposals described in the Companys definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 3, 2020.

The record date for the Special Meeting remains October 28, 2020. Stockholders of record may vote at the reconvened Special Meeting, vote by proxy using the proxy card enclosed with the Companys definitive proxy statement, vote by proxy via facsimile, email or on the Internet. Whether or not stockholders of record plan to attend the reconvened Special Meeting, the Companys Board of Directors and management urge them to vote by proxy to ensure their vote is counted. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

A copy of the Companys proxy statement as previously filed with the SEC is available at no charge on the SEC website at http://www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Companys website at https://investors.predictive-oncology.com/ or by contacting the Companys Corporate Secretary at (651) 389-4806 or by mail to Corporate Secretary, Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, MN 55121.

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IRJames Carbonara(646)-755-7412

See the original post:
Predictive Oncology Announces Adjournment of Special Meeting - GlobeNewswire

The cell therapy technologies market is expected to gain immense growth opportunities through the forecast period of 2019-2029 owing to the rising influence of cell therapies across the life sciences sector. The overwhelming need for novel and enhanced therapies for a variety of diseases and disorders may bring extensive growth prospects for the cell therapy technologies market during the forecast period.

The increased funding by the government may also prove to be a great growth prospect for the cell therapy technologies market. The precision medicine sector is evolving at a rapid rate across the globe. In this, a patient is given personalized treatment and is useful in making more accurate decisions. Thus, this factor may boost the growth of the cell therapy technologies market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6943

Cellular therapy is the transplantation of human cells to replace cells or tissues. This therapy can be used for treating various diseases and disorders. The evolution of cell therapy technologies is bringing immense advancements across the sector. This therapy is used mainly for nervous system disorders and cancer. The growing cases of these diseases may further invite promising growth.

On the basis of product, the cell therapy technologies market can be segmented into consumables, cell processing equipment, single-use equipment, other equipment, and systems and software. Based on cell type, the cell therapy technologies market can be classified into stem cells, T-cells, and other cells. Cell therapy technology is utilized expansively in biopharmaceutical and biotechnology companies and CROs, and research institutes and cell banks.

The enhancements in cell therapy technology research through immense investments from various sectors may invite prominent growth prospects for the cell therapy technologies market.

This report has extensive information on a plethora of aspects related to the growth of the cell therapy technologies market. The L.E.A.P mechanism applied by the researchers enables a 360-degree view of the cell therapy technologies market. The CXOs derive the perfect information that allows them to chalk out their business strategy accordingly. This report also has scrutinized information about the novel coronavirus outbreak and its effect on the cell therapy technologies market.

Cell Therapy Technologies Market: Competitive Insights

The cell therapy technologies market is highly fragmented. Numerous players are involved in intense competition for gaining a prominent position among the end-users. The players are also involved in expansion activities through mergers and acquisitions. Some well-entrenched players in the cell therapy technologies market are Danaher Corporation, CellGenix GmbH, IxCells Biotechnology, Wilson Wolf Corporation, SIRION Biotech GmbH, Dickinson and Company, and FUJIFILM Irvine Scientific.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6943&ltype=S

Cell Therapy Technologies Market: COVID-19 Impact

The COVID-19 impact may offer bright opportunities for the cell therapy technologies market to gain growth. The rising transmission of COVID-19 has led to rapid research and development activities in terms of an effective drug or vaccine. Cell-based research and technologies play an important role in the discovery of vaccines. Hence, this aspect may bring expansive growth prospects for the cell therapy technologies market.

Cell Therapy Technologies Market: Regional Prospects

The cell therapy technologies market in North America may gain a dominant position throughout the forecast period of 2019-2029. The maximizing research and development activities across the region for a good COVID-19 vaccine may bring profitable growth for the cell therapy technologies market. Robust healthcare expenditure, rising disposable income, and growing healthcare awareness may invite promising growth.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6943

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

See more here:
Cell Therapy Technologies Market | Extensive Information on a Plethora of Aspects Related to the Growth of the Market - BioSpace

There may be nothing quite as gut-wrenching as sitting at the bedside of a loved one, watching helplessly as their life comes to an end. Perhaps the only thing more painful is when that loved one no longer recognizes you, slipping away not knowing who it was holding their hand.

November is deemed Alzheimers Awareness Month. Though with the degenerative brain disease now affecting roughly 5.8 million Americans and their families today, its perhaps not so much an increase of awareness thats needed, but rather a desperate need for effective treatment.

Alzheimers is the only disease among the top 10 causes of death in America that cannot be prevented, cured or even slowed. Over a decade and billions of dollars have been spent on research to find a cure for Alzheimers, yet none have thus far proved real clinical benefit. If the elusive cure for Alzheimers isnt found soon, scientists estimate that by 2050 someone in the United States will develop the disease every 33 seconds.

While these statistics paint a pretty bleak picture, Cynthia Lemere, Ph.D., Associate Professor of Neurology at Brigham and Womens Hospital and Harvard Medical School, assured BioSpace that hope is not lost. Despite the many failed drug trials, Lemere says the horizon is finally looking optimistic and expects to see multiple treatments approved within the next few years.

Any therapy developed at this point is going to be probably good for one subsection of that 5.8 million people with Alzheimers disease. And maybe not even that population, but maybe the population that doesnt yet have Alzheimers disease but has the changes going on in their brain of Alzheimers, so we know that theyre on the track, Lemere said.

While no real treatment is yet approved, diagnostic capabilities have grown exponentially. When Lemere first started in the neurology field, a true Alzheimers diagnosis couldnt be given until autopsy. The past decade has shown that the pathology of the disease starts in the brain roughly 20 years before clinical symptoms. PET scans can determine those on a trajectory to develop Alzheimers and with new biomarker testing working towards FDA approval, theyll be able to predict onset of clinical symptoms.

Knowing those who are most likely to develop this degenerative brain disease and when opens opportunities for clinical trials that are in the works. The majority of treatments being developed right now are targeting that window before cognitive decline. There are currently 2,050 interventional studies listed on clinicaltrials.gov around the world for the treatment of AD.

One buzzworthy drug in the news is Biogens aducanumab. Back in March 2019, Biogen stopped two Phase III trials for the antibody drug based on an interim futility analysis that indicated a lack of efficacy. But after a full collection of their data, Biogen found there was indeed efficacy in the higher dosage group who received over 10 doses.

This left them with two very different sets of trial results EMERGE with a positive reading and ENGAGE with a negative. Lemere believes the evidence in the EMERGE trial was strong enough to show positive clinical benefits. Despite much criticism and doubts surrounding aducanumab, Biogen took it to the FDA with hopes for approval and received a harsh vote from an independent advisory committee. No word yet from the FDA. Lemere predicts the FDA will call for another, large Phase III study to confirm the positive result at the higher dose for the full study. Lemere consults with Biogen for the companys Alzheimers education program and is not involved with their drug development programs.

The main breakthrough in the past year for pharmaceutical treatment of AD is that researchers finally know what the right target is - a toxic amyloid oligomer formation that is a key driver for the disease. Biogen isnt the only one targeting it with their drug candidates. Also in the race are Alzheon with ALZ-801, Eisais BAN2401 and Roches gantenerumab.

Unlike the intravenous antibody candidates from the other three, Alzheons ALZ-801 is an orally administered amyloid oligomer inhibitor. Alzheon recently dosed their first patients in a Phase II biomarker study in APOE4 carriers. Patients with an APOE4 gene are at a much higher risk for developing Alzheimers, particularly if you were passed two of the genes. In August, the National Institute of Aging awarded Alzheon an unprecedented $47 million grant to assist with a Phase III clinical trial of ALZ-801. The trial is slated to start at the beginning of next year with a timeline of 2-3 years to complete. This Phase III will be dosing younger people with Alzheimers pathology to test for primary prevention, intervening before clinical symptoms appear.

A Shanghai-based biotech is targeting AD in a completely different way. Instead of targeting amyloid in the brain, Green Valleys candidate is going after the gut. GV-971 is an oral capsule with its primary ingredient derived from seaweed to therapeutically harnesses the abnormal production of amino acids, infiltration of immune cells to the brain, and in turn neuroinflammation via remodeling the gut microbiota. Reactions to this approach range from excitement to cautious optimism to downright skepticism. Time should soon tell if theres something to this approach as Green Valley has now identified its first patient for its Phase III trial in the US with the initial dose coming soon.

Drug developers arent the only ones trying to stop the devastating progression of AD. A research team at MIT found that in Alzheimer's mouse models, the right brain waves can drive microglia, scavenger cells that remove damaged neurons and infections in the central nervous system, to consume the toxic amyloid protein deposits. More research is being done in this area to explore this as a potential option for treatment in humans to reduce amyloid deposits in the brain.

Lemere listed off multiple research projects in the works for Alzheimers prevention therapies to prevent free-radical formation and reduce oxidative stress in the brain, studies into the importance of vascular health and its impact on AD, the effects of diet and exercise, and more. One study found significant results in patients using aggressive blood pressure therapy. People that had lowered their blood pressure and kept it around 120, compared to the control group hovering around 140, showed a significant slowing of the rate of visible cognitive impairment.

The Alzheimers Association, of which Lemere is a member of the medical and scientific advisory group, is sponsoring a lifestyle intervention study in the U.S. called POINTER, that takes into account exercise, nutrition, social interactions, cognitive stimulation and management of comorbidities to protect cognitive function in healthy older adults who are at an increased risk of cognitive decline.

The big point is that probably none of these is going to work by itself, Lemere said.

Rather she sees a future in which a doctor who sees Alzheimers pathology brewing in a patient will recommend a multi-prong defense.

I think its going to be a combination of treatments. And its not going to be the same combination for each person, Lemere said. Its going to be dependent on whatever else is going on with them. Because Alzheimers rarely occurs by itself. There are usually other comorbidities. So ultimately, I think it will be more personalized medicine and combination therapy.

In 2020 alone, the National Institutes of Health is expected to spend $2.8 billion on Alzheimers research. Costing the U.S. $277 billion a year, its the most expensive disease in America. Annual cost of care is projected to increase to $1.1 trillion by 2050. While the financial burden is exorbitantly high, for family members and caregivers its the emotional cost that leaves the deepest scars.

Arkansas resident Linda Crafton knows firsthand the devastating effects Alzheimers has on a family.

To me, its worst disease known to mankind. I used to think the way I lost my dad, which was an instant death, was the hardest way to lose someone, Crafton said. I now know that was wrong. The hardest way to lose your parent is day by day, little by little, an inch at a time.

Craftons mother and five of her mothers seven siblings were victims of the aggressive disease. She said shes in a generation of cousins who now live in fear of the future, wondering which of them will be the first to show the signs, the first to receive their own diagnosis.

Time magazine writer Jeffrey Kluger said, Suffering is always hard to quantify especially when the pain is caused by as cruel a disease as Alzheimer's. Most illnesses attack the body; Alzheimer's destroys the mind and, in the process, annihilates the very self.

Though a cure for Alzheimers has frustrated scientists for years, theyre closer now than theyve ever been before.

According to the Alzheimers Association, a lack of volunteers for clinical trials is one of the greatest obstacles slowing the progress of potential new treatments. If you or someone you love is on a trajectory for the development of Alzheimers disease, the association offers a free TrialMatch service to connect volunteers with clinical trials to advance research.

Most read today on BioSpace:

More:
Potential for an Alzheimer's Treatment Appears to Be Closer Than Ever - BioSpace

Latest launched research document on Pharma Clinical Trial Digitization Market study of 350 Pages provides detailed analysis with presentable graphs, charts and tables. This report covers a detailed study of the Pharma Clinical Trial Digitization Market size, growth, and share, trends, consumption, segments, application and Forecast 2027. The Research Study presents a complete assessment of the Market and highlights future trend, growth factors & drivers, leaders opinions, facts, and primary validated market data. The research study provides estimates for Pharma Clinical Trial Digitization Forecast till 2027. Pharma Clinical Trial Digitization Report is a comprehensive business study on the current state of industry which analyses innovative strategies for business growth and describes important factors such as top manufacturers, production value, key regions, and growth rate.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharma-clinical-trial-digitization-market&AB

Pharma Clinical Trial Digitization Market is accelerating owing to the demand of personalized medicine. The enhancement in the digital pharma services to keep the track of medication through the various components namely individualized drug printing, drug impact monitoring, bioprinting and others are defining the potential future of the pharma clinical trial digitization market during the forecast period of 2020 to 2027.

This upgradation of healthcare IT infrastructure and technological assistance being provided on vast scale is driving the market growth at the rate of 5.70% annual for the mentioned seven years. This momentum will be maintained by rising practice of individualized drug printing.

Pharma Clinical Trial Digitization Market report covers strategic profiling of key players in the market, comprehensively analyzing their core competencies, and their strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions which are applicable for the businesses with which they can take better steps to improve their strategies to sell goods and services. Market research study presents actionable market insights which help create sustainable and money-spinning business strategies. An absolute way to forecast what future holds is to comprehend the trend today. Thus, with this Pharma Clinical Trial Digitization business report, more important aspects of the Pharma Clinical Trial Digitization industry can be focused.

Pharma Clinical Trial Digitization Market Scenario

According to Data Bridge Market Research the Pharma Clinical Trial Digitization market is attaining a significant growth in the developing economies during the forecast period of 2020-2027 due to factors such as introduction of medical robots in hospitals, improving quality life of people, rising popularity of technologically advanced surgical robots and increasing diagnosis of diseases will boost the growth of the market. Pharma Clinical Trial Digitization Market is becoming more competitive every year with surgical robots will expect to attain maximum share during the period of 2020-2027. The Data bridge market research new reports highlight the major growth factors and opportunities in the Pharma Clinical Trial Digitization Market.

To Get the Short-Term and Long-Term Impact of COVID-19 on thisMarket@https://www.databridgemarketresearch.com/request-covid-19/global-pharma-clinical-trial-digitization-market&Ab

List of Significant Vendors Operating in this market include:

Antidote Technologies, Inc.AparitoClinerion Ltd.CliniOps, Inc.ConsilxDeep 6 AIKoneksa Health Inc.Medidata SolutionsOraclePatientsLikeMeTrialbeeTriNetX, Inc.Veeva Systems.Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&ab

This Pharma Clinical Trial Digitization Market Research document takes into consideration several industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company. It consists of most-detailed market segmentation, systematic analysis of major market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. The market insights and analysis provided in this market research document are based upon SWOT analysis on which businesses can trust confidently. This Pharma Clinical Trial Digitization report is produced by chewing over several fragments of the present and upcoming market scenario.

Global Pharma Clinical Trial Digitization Market Segments & Geographic Analysis:

By Services (Drug Dose Adjustment, Drug Impact Monitoring, Medical Prescription System, Bioprinting, Preventive Therapy, Individualized Drug Printing)

By Application (Clinical Data Management, Trial Monitoring, Patient Recruitment and Enrollment)

By Themes (Digital Continuity Across Clinical Trial IT Systems, Patient-centric Remote and Virtual Trial Design, Direct-to-patient Home Services)

Pharma Clinical Trial Digitization Market-Geographical Segment

North America (Canada, United States & Mexico)Europe (Germany, the United Kingdom, BeNeLux, France, Russia & Italy)Asia-Pacific (Japan, South Korea, China, India & Southeast Asia)South America (Argentina, Brazil, Peru, Colombia, Etc.)Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)Global Pharma Clinical Trial Digitization Market Scope and Market Size

Pharma clinical trial digitization market is segmented of the basis of services, application and themes. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.

Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.

The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Years considered for this report:o Historical Years: 2010-2019o Base Year: 2019o Estimated Year: 2020o Pharma Clinical Trial Digitization Market Forecast Period: 2020-2027

With tables and figures helping analyses worldwide Global Pharma Clinical Trial Digitization market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Pharma Clinical Trial Digitization Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition byCompany:Here, the competition in the Worldwide Pharma Clinical Trial Digitization Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Pharma Clinical Trial Digitization Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Pharma Clinical Trial Digitization Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Pharma Clinical Trial Digitization Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Pharma Clinical Trial Digitization Market.

Market Forecast:Here, the report offers a complete forecast of the global Pharma Clinical Trial Digitization Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Read the rest here:
Pharma Clinical Trial Digitization Market Size, Share, Revenue, Demand and Forecasted Healthcare Industry with Upcoming Trends and Expectations by...

Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting

The rest is here:
Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced today that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. DANYELZA (naxitamab-gqgk) was approved by the U.S. FDA on November 25, 2020. Additionally, Y-mAbs plans to resubmit the amended BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or in early 2021.

The rest is here:
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

WILLIAMSVILLE, N.Y., Dec. 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it will be presenting at the 13th Annual LD Micro Main Event Conference on Monday, December 14, 2020, at 9:20 a.m. ET. James A. Mish, chief executive officer of 22nd Century Group, will be presenting to a live, virtual audience.

Read the original post:
22nd Century Group to Present at 13th Annual LD Micro Main Event Conference

Here is the original post:
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)

VALNEVA

Here is the original post:
Valneva - Déclaration d’actions et de droits de vote – NOVEMBRE 2020